Study on Irinotecan, Fluorouracil, Oxaliplatin, and Calcium Folinate for Patients with Resectable Stomach and Gastroesophageal Junction Cancer

2 1 1 1

What is this study about?

This clinical trial is focused on studying the treatment of resectable gastric and gastroesophageal junction adenocarcinoma, which are types of cancer that occur in the stomach and the area where the stomach meets the esophagus. The treatment being tested is a combination of medications known as FOLFOXIRI, which includes fluorouracil, oxaliplatin, calcium folinate, and irinotecan hydrochloride trihydrate. These medications are given through an intravenous infusion, which means they are delivered directly into the bloodstream through a vein.

The purpose of this study is to evaluate how well this combination of medications works in treating the cancer before and after surgery. Participants in the study will receive the treatment over a period of time, and their response to the treatment will be monitored. The study aims to determine the rate of response to the treatment according to specific criteria, as well as to assess the safety and potential side effects of the treatment.

Throughout the study, participants will be closely monitored for any changes in their condition, and the effectiveness of the treatment will be evaluated at various points. The study will also look at the rate of successful surgical removal of the cancer and track the participants’ health over several years to understand the long-term effects of the treatment. This research is part of a larger effort to improve treatment options for patients with these types of cancer.

1 initiation of treatment

Upon joining the study, the treatment begins with the administration of a combination of medications. These medications include fluorouracil, oxaliplatin, calcium folinate, and irinotecan hydrochloride trihydrate.

All medications are given through an intravenous route, which means they are administered directly into a vein.

2 perioperative treatment phase

The treatment is part of a perioperative phase, which involves administering the medications before and after surgery to treat gastric and gastroesophageal junction adenocarcinoma.

The goal is to assess the response of the cancer to the treatment using specific criteria.

3 surgery

Surgery is performed to remove the cancerous tissue. The timing of the surgery is determined based on the response to the initial treatment phase.

The effectiveness of the surgery is evaluated within 30 days post-operation.

4 post-surgery treatment

After surgery, the treatment continues with the same combination of medications to ensure any remaining cancer cells are targeted.

This phase is crucial for improving the chances of a successful outcome.

5 follow-up and monitoring

Regular follow-up appointments are scheduled to monitor the patient’s health and the effectiveness of the treatment.

These follow-ups occur at 12, 18, 24, 30, 36, 48, and 60 months from the start of the trial.

6 evaluation of treatment outcomes

The primary outcome is the rate of response to the treatment, assessed within 30 days after surgery.

Secondary outcomes include the rate of successful surgery, completion of treatment, survival rates, and monitoring of any side effects or complications.

Who Can Join the Study?

The patient must have a type of cancer called gastric or gastroesophageal junction adenocarcinoma that can be surgically removed.
The patient must be able to follow the study’s rules and procedures.
A surgeon must confirm that the patient can have surgery.
The cancer must be at a specific stage, described as cT2-4a or cN+, cM0. This means the tumor has grown to a certain size or spread to nearby lymph nodes but not to other parts of the body.
The patient must be 18 years or older.
The patient must have a WHO performance status of 1 or less, which means they are fully active or have some symptoms but can still do light work.
If there is a suspicion of cancer spread to the lining of the abdomen (called peritoneal carcinomatosis), it must be ruled out using a procedure called laparoscopy.
The patient must have certain blood test results within normal limits, including:
- Hemoglobin (a protein in red blood cells) must be more than 90 g/L. Blood transfusions are allowed to reach this level.
- Absolute neutrophil count (ANC), a type of white blood cell, must be at least 1.5 x 10⁹/L.
- Platelets, which help with blood clotting, must be at least 75 x 10⁹/L.
- Bilirubin, a substance made by the liver, must be 1.5 times the upper limit of normal (ULN) or less.
- ALAT, a liver enzyme, must be 3 times the ULN or less.
- Creatinine, a waste product in the blood, must be 1.5 times the ULN or less.
Women who can have children and men in relationships with such women must use highly effective birth control methods during the study and for 6 months after. These methods include:
- Hormonal birth control that stops ovulation, taken by mouth, vaginally, or through the skin.
- Progestogen-only hormonal birth control that stops ovulation, taken by mouth, by injection, or as an implant.
- An intrauterine device (IUD) or a hormone-releasing system placed in the uterus.
- Bilateral tubal occlusion, a procedure to block the fallopian tubes.
- A partner who has had a vasectomy, a procedure to prevent sperm from being released.
- Choosing not to have sexual intercourse, if this is the usual and preferred lifestyle of the patient.
The patient must sign a document called informed consent, which explains the study and confirms their willingness to participate.

Who Cannot Join the Study?

Patients who have a different type of cancer than the one being studied.
Patients who have had previous treatment that might interfere with the study results.
Patients with other serious health conditions that could affect their safety during the study.
Patients who are unable to follow the study procedures or attend required visits.
Patients who are pregnant or breastfeeding.
Patients who are participating in another clinical trial at the same time.
Patients who have allergies to the study medication or its ingredients.
Patients who have a history of substance abuse that could interfere with the study.
Patients who have certain infections that could affect their participation.
Patients who are not able to give informed consent to participate in the study.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country	Status
Oslo Universitetssykehus HF	Oslo	Norway

Other Sites

Site Name	City	Country
Region Skane Skanes Universitetssjukhus	Lund	Sweden
Karolinska University Hospital	Solna	Sweden
Region Kronoberg	Vaxjo	Sweden

Trial status

Country	Status	Recruitment Start
Norway	Not recruiting	01.04.2018
Sweden	Not recruiting	01.04.2018

Trial locations

Investigated drugs:

Irinotecan: This medication is used in combination with other drugs to treat certain types of cancer. In this trial, it is part of a treatment regimen for gastric and gastroesophageal junction adenocarcinoma. It works by interfering with the growth of cancer cells, which are eventually destroyed.

FOLFOXIRI: This is a combination chemotherapy regimen that includes several drugs, including irinotecan, used to treat cancer. It is designed to attack cancer cells in different ways, making it more effective than using a single drug. In this trial, FOLFOXIRI is used as a perioperative treatment, meaning it is given around the time of surgery to help shrink the tumor and improve surgical outcomes.

Investigated diseases:

Resectable Gastric and Gastroesophageal Junction Adenocarcinoma – This is a type of cancer that occurs in the stomach or where the stomach meets the esophagus. It is characterized by the growth of malignant cells in the lining of these areas. The disease progresses as the cancer cells invade deeper layers of the stomach or esophageal wall and can spread to nearby lymph nodes or other organs. Early stages may not show symptoms, but as it advances, it can cause difficulty swallowing, weight loss, and stomach pain. The term “resectable” indicates that the tumor can potentially be removed through surgery. The progression and impact of the disease depend on the size and spread of the tumor at the time of diagnosis.

Trial ID:

2023-509044-96-00

NCT ID:

NCT03773367

Trial Phase:

Therapeutic exploratory (Phase II)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on Irinotecan, Fluorouracil, Oxaliplatin, and Calcium Folinate for Patients with Resectable Stomach and Gastroesophageal Junction Cancer

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?